What effect have tariffs had on the manufacture and distribution of medical and how has the industry coped?
Over the past year, the medical device industry has been forced to navigate a rapidly shifting trade environment as new and proposed
Medical devices rely on highly globalized supply chains, with critical components, raw materials, and subassemblies often sourced from multiple countries. Tariffs on metals, electronics, and finished components increased costs at nearly every stage of production, leaving manufacturers with difficult choices: absorb higher expenses, pass costs along to hospitals and health systems, or delay investments in research and development. For an industry already operating under tight pricing pressures and
The uncertainty surrounding tariff policy also proved disruptive. Rapidly changing rules made it difficult for companies to plan capital investments, negotiate long-term supplier contracts, or commit to expanding domestic manufacturing. Smaller and mid-sized device companies—often more dependent on a narrow supplier base—faced disproportionate risk, raising concerns about consolidation and reduced competition in the market.
From a clinical perspective, industry leaders warned that tariffs could slow innovation, limit product availability, and exacerbate supply shortages, particularly for lower-margin but essential devices. At the same time, hospitals and physician practices worried about rising acquisition costs in an era of flat or declining reimbursement.
Taken together, these concerns underscore why tariffs became a focal point of debate within the medical device sector—highlighting the complex interplay between trade policy, healthcare economics, and patient care. Medical Economics spoke with Casey Hite, CEO,
